Masong, Harmelene C.

HRN: 10-67-36  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/24/2022
CEFTAZIDIME 1GM (VIAL)
11/24/2022
12/01/2022
IV
870mg
Q8
AML, Oral Mucositis
Waiting Final Action 
11/24/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/24/2022
12/01/2022
IV
390mg
OD
Aml, Mucositis
Waiting Final Action 
11/24/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/24/2022
12/01/2022
IV
200mg
Q6
Oral Mucositis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: